Codiak BioSciences, Inc. expected to post a loss of 89  cents a share - Earnings Preview

Codiak BioSciences,.

02/05/2022 18:01

* Codiak BioSciences, Inc.  CDAK.OQ   CDAK.O  is expected
to show
a fall in quarterly revenue when it reports  results on May 4
(estimated). 
    * The Cambridge Massachusetts-based  company is expected to
report
 a 68.2% decrease in revenue to $4.2 million from $13.19 million
a year ago, according to the mean estimate from 3 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Codiak BioSciences,
Inc.
is for a loss of 89 cents per share. For the same quarter last
year, the company reported a loss of 51 cents per share.
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 2.0%
in the last three months. ​
    * Wall Street's median 12-month price target for Codiak
BioSciences, Inc. is $21​, above​ its last closing price
of $2.96. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.98       -0.94      -0.74     Beat    21.6
 Sep. 30 2021  -0.94       -0.94      -0.97     Missed  -2.6
 Jun. 30 2021  -1.04       -1.05      -0.99     Beat    5.4​
 Mar. 31 2021  -1.10       -1.09      -0.51     Beat    53.4
 ​​Dec.        -1.82       -1.54      -1.14     Beat    25.8
 31 2020                                                
 Sep. 30 2020  -5.51       -5.50      -12.83    Missed  -133.4
                                                        ​
 This summary was machine generated May 2 at 17:00 GMT.  All
figures in US dollars  unless otherwise stated